These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1380905)

  • 21. Serum and prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate.
    Wagenlehner FM; Lunz JC; Kees F; Wieland W; Naber KG
    J Chemother; 2006 Oct; 18(5):485-9. PubMed ID: 17127224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of ofloxacin and norfloxacin concentration in prostatic tissues in patients undergoing transurethral resection of the prostate.
    Chen J; Chen RR; Huang HS
    J Formos Med Assoc; 2001 Aug; 100(8):548-52. PubMed ID: 11678006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical efficacy of tosufloxacin in children with pneumonia due to Mycoplasma pneumoniae].
    Sakata H
    Jpn J Antibiot; 2012 Jun; 65(3):173-9. PubMed ID: 23173293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diffusion of piperacillin, cefotiam, minocycline, amikacin and ofloxacin into the prostate.
    Goto T; Makinose S; Ohi Y; Yamauchi D; Kayajima T; Nagayama K; Hayami H
    Int J Urol; 1998 May; 5(3):243-6. PubMed ID: 9624555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Preventive chemotherapy after transurethral prostatectomy: a randomized study].
    Yoshida O; Arai Y; Takeuchi H; Fukuyama T; Hida S; Ikeda T; Okabe T; Kuo SY; Kounami T; Nakagawa T
    Hinyokika Kiyo; 1993 May; 39(5):491-6. PubMed ID: 7686715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Penetration of orally administered prulifloxacin into human prostate tissue.
    Giberti C; Gallo F; Rosignoli MT; Ruggieri A; Barattè S; Picollo R; Dionisio P
    Clin Drug Investig; 2009; 29(1):27-34. PubMed ID: 19067472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Terbium sensitized determination of tosufloxacin using electrochemiluminescence method.
    Liu Y; Chen S; Zhao H; Jin L
    Anal Sci; 2005 Apr; 21(4):373-5. PubMed ID: 15844328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of intravenously administered pefloxacin in the prostate; perspectives for its application in surgical prophylaxis.
    Giannopoulos A; Koratzanis G; Giamarellos-Bourboulis EJ; Stinios I; Chrisofos M; Giannopoulou M; Giamarellou H
    Int J Antimicrob Agents; 2001 Mar; 17(3):221-4. PubMed ID: 11282268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Tosufloxacin tosilate].
    Shimada K
    Jpn J Antibiot; 1990 Apr; 43(4):583-602. PubMed ID: 2199687
    [No Abstract]   [Full Text] [Related]  

  • 30. Pulmonary infiltration with eosinophilia (PIE) syndrome induced by antibiotics, PIPC and TFLX during cancer treatment.
    Yamamoto T; Tanida T; Ueta E; Kimura T; Doi S; Osaki T
    Oral Oncol; 2001 Jul; 37(5):471-5. PubMed ID: 11377237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
    Naber KG; Sörgel F; Kees F; Schumacher H; Metz R; Grobecker H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():199-207. PubMed ID: 2462556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of lomefloxacin in the treatment of chronic prostatitis.
    Scelzi S; Travaglini F; Nerozzi S; Dominici A; Ponchietti R; Novelli A; Rizzo M
    J Chemother; 2001 Feb; 13(1):82-7. PubMed ID: 11233805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salmonella excretion after cessation of tosufloxacin therapy in acute nontyphoid salmonella enterocolitis.
    Ohnishi K; Kimura K
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1892-3. PubMed ID: 11353646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose.
    Gee T; Andrews JM; Ashby JP; Marshall G; Wise R
    J Antimicrob Chemother; 2001 Apr; 47(4):431-4. PubMed ID: 11266415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical and bacteriological study of sparfloxacin on bacterial prostatitis].
    Suzuki K; Horiba M; Naide Y; Shinoda M; Hibi H
    Hinyokika Kiyo; 1992 Jan; 38(1):121-8. PubMed ID: 1312292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral administration of fluoroquinolones in the treatment of typhoid fever and paratyphoid fever in Japan.
    Ohnishi K; Kimura K; Masuda G; Tsunoda T; Obana M; Yoshida H; Goto T; Sakaue Y; Kim YK; Sakamoto M; Sagara H
    Intern Med; 2000 Dec; 39(12):1044-8. PubMed ID: 11197787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro susceptibility of Nocardia spp. to a new fluoroquinolone, tosufloxacin (T-3262).
    Yazawa K; Mikami Y; Uno J
    Antimicrob Agents Chemother; 1989 Dec; 33(12):2140-1. PubMed ID: 2619279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Ofloxacin concentration in prostatic tissue].
    Kawauchi A; Kamoi K; Ohne T; Imada N; Kitamori T; Terasaki T; Watanabe H
    Hinyokika Kiyo; 1993 Dec; 39(12):1191-3. PubMed ID: 7506868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human prostatic tissue concentrations of rosoxacin.
    Jensen KM; Patel RB; Welling PG; Madsen PO
    Prostate; 1982; 3(5):523-9. PubMed ID: 7145776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Penetration of lomefloxacin into human prostatic tissue.
    Leroy A; Grise P; Dhib M; Valtchev B; Fillastre JP
    Urology; 1991 Aug; 38(2):192. PubMed ID: 1877143
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.